Prodrug of Epigallocatechin-3-gallate Alleviates Choroidal Neovascularization Via Down-Regulating HIF-1/VEGF/VEGFR2 Pathway and M1 Type Macrophage/microglia Polarization

Jiaowen Xu,Yuanyuan Tu,Ying Wang,Xun Xu,Xiaodong Sun,Laiqing Xie,Qingliang Zhao,Yang Guo,Yonghui Gu,Jingxia Du,Shu Du,Manhui Zhu,E. Song
DOI: https://doi.org/10.1016/j.biopha.2019.109606
IF: 7.419
2020-01-01
Biomedicine & Pharmacotherapy
Abstract:Age-related macular degeneration (AMD) is a leading cause of vision loss in the elderly and is attributed to choroidal neovascularization (CNV), which is a feature of wet AMD. The hypoxia-inducible factor-1 alpha (HIF-1 alpha)/vascular endothelial growth factor (VEGF)/VEGF receptor 2 (VEGFR2) pathway contributes to the pathogenesis of CNV. M1-type macrophages/microglia secrete interleukin-6 (IL-6) and tumor necrosis factor a (TNF-alpha), facilitating the development of CNV. Epigallocatechin-3-gallate (EGCG) is a kind of polyphenol in green tea that exerts anti-inflammatory and antiangiogenic effects. In this study, a prodrug of EGCG (pro-EGCG) alleviated mouse laser-induced CNV leakage and reduced CNV area by down-regulating HIF-1 alpha/VEGF/VEGFR2 pathway; M1-type macrophage/microglia polarization; as well as endothelial cell viability, proliferation, migration and tube formation, indicating a novel potential therapy for AMD.
What problem does this paper attempt to address?